Keywords: D-Pharm, Jiangsu NHWA, Epilepsy, DP-VPA, China

D-Pharm in deal with China’s Jiangsu NHWA for epilepsy drug DP-VPA

Article | 02 June 2011

Israel-based clinical-stage biopharma company D-Pharm (TASE: DPRM) has entered into a licensing and co-development agreement with China’s Jiangsu ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

D-Pharm

Jiangsu NHWA

Go to company listing